ipilimumab,int230-6,pembrolizumab,nivolumab
bms,intensity therapeutics,merck
['11515', 'ipilimumab', 'int230-6', 'sarcoma']
 #sarcoma poster discussion session at #asco2022 abs 11515 novel drug #int230-6 shows promising activity in #sts as monotherapy and in combination with #ipilimumab and may extend survival when dosed to &gt;40% ttb as shown in a phase ii clinical study of 26 pts. #meded
Independent & international experts in #Sarcoma. #MedEd communicators, keeping you up to date with research & medical news in Sarcoma. Part of https://t.co/qM8Tca8PQX